Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial

被引：1
|
作者：
de Souza, M. S. [1 ]
Trichavaroj, R. [1 ]
Schuetz, A. [1 ]
Chuenarom, W. [1 ]
Phuang-ngem, Y. [1 ]
Jongrakthaitae, S. [1 ]
Ratto-Kim, S. [2 ]
Nitayaphan, S. [1 ]
Dally, L. [3 ]
Rerks-Ngam, S. [4 ]
Tartaglia, J. [5 ]
Francis, D. [6 ]
Michael, N. L. [2 ]
Paris, R. M. [1 ]
Kim, J. H. [2 ]
机构：
[1] US Mil HIV Res Program AFRIMS, Bangkok, Thailand
[2] US Mil HIV Res Program, Rockville, MD USA
[3] EMMES Corp, Rockville, MD USA
[4] Minist Publ Hlth, Nonthaburi, Thailand
[5] Sanofi Pasteur, Toronto, ON, Canada
[6] Global Solutat Infect Dis, San Francisco, CA USA
来源：
RETROVIROLOGY | 2009年 / 6卷
关键词：
Humoral Immune Response; Vaccine Candidate; Vaccine Trial; Recombinant Form; Vaccine Antigen;
D O I：
10.1186/1742-4690-6-S3-O52
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial
    Heather A. Prentice
    Philip K. Ehrenberg
    Karen M. Baldwin
    Aviva Geretz
    Charla Andrews
    Sorachai Nitayaphan
    Supachai Rerks-Ngarm
    Jaranit Kaewkungwal
    Punnee Pitisuttithum
    Robert J. O’Connell
    Merlin L. Robb
    Jerome H. Kim
    Nelson L. Michael
    Rasmi Thomas
    Immunogenetics, 2014, 66 : 299 - 310
  • [32] A phase 112 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (Subtype E) candidate vaccine - ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivolent gp120 (CM235/SF2) boost
    Thongcharoen, Prasert
    Suriyanon, Vinai
    Paris, Robert M.
    Khamboonruang, Chirasak
    de Souza, Mark S.
    Ratto-Kim, Silvia
    Karnasuta, Chitraporn
    Polonis, Victoria R.
    Baglyos, Lynn
    El Habib, Raphaelle
    Gurunathan, Sanjay
    Barnett, Susan
    Brown, Arthur E.
    Birx, Deborah L.
    McNeil, John G.
    Kim, Jerome H.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (01) : 48 - 55
  • [33] HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial
    Prentice, Heather A.
    Ehrenberg, Philip K.
    Baldwin, Karen M.
    Geretz, Aviva
    Andrews, Charla
    Nitayaphan, Sorachai
    Rerks-Ngarm, Supachai
    Kaewkungwal, Jaranit
    Pitisuttithum, Punnee
    O'Connell, Robert J.
    Robb, Merlin L.
    Kim, Jerome H.
    Michael, Nelson L.
    Thomas, Rasmi
    IMMUNOGENETICS, 2014, 66 (05) : 299 - 310
  • [34] Vaccine Induced Seroreactivity Induced by ALVAC-HIV and AIDSVAXB/E Prime-boost Vaccinations with Varying Late Boosts (RV306)
    Wansom, Tanyaporn
    Akiparat, Siriwat
    Pitisutthitum, Punnee
    Nitayaphan, Sorachai
    Chariyalertsak, Suwat
    Eamsila, Chirapa
    Wongwarapat, Kanlaya
    Karasavvas, Nicos
    Sinangil, Faruk
    Phogat, Sanjay
    Robb, Merlin
    Michael, Nelson
    Kim, Jerome
    Vasan, Sandhya
    O'Connell, Robert
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 397 - 397
  • [35] Ex Vivo Evaluation of Mucosal Cytokine Responses to in Vivo Vaccination with ALVAC-HIV/AIDSVAX® B/E of Non-human Primates (NHPs) and Humans
    Herrera, Carolina
    Veazey, Ronald
    Schuetz, Alexandra
    Olejniczak, Natalia
    Chenine, Agnes-Laurence
    Phogat, Sanjay
    Sinangil, Faruk
    Nitayaphan, Sorachai
    Kaewkungwal, Jaranit
    Pitisuttithum, Punnee
    Rerks-Ngarm, Supachai
    Michael, Nelson L.
    Robb, Merlin L.
    Excler, Jean-Louis
    O'Connell, Robert J.
    Vasan, Sandhya
    Kim, Jerome H.
    Shattock, Robin J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 75 - 75
  • [36] Molecular Evolution of the HIV-1 Thai Epidemic between the Time of RV144 Immunogen Selection to the Execution of the Vaccine Efficacy Trial
    Kijak, Gustavo H.
    Tovanabutra, Sodsai
    Rerks-Ngarm, Supachai
    Nitayaphan, Sorachai
    Eamsila, Chirapa
    Kunasol, Prayura
    Khamboonruang, Chirasak
    Thongcharoen, Prasert
    Namwat, Chawetsan
    Premsri, Nakorn
    Benenson, Michael
    Morgan, Patricia
    Bose, Meera
    Sanders-Buell, Eric
    Paris, Robert
    Robb, Merlin L.
    Birx, Deborah L.
    De Souza, Mark S.
    McCutchan, Francine E.
    Michael, Nelson L.
    Kim, Jerome H.
    JOURNAL OF VIROLOGY, 2013, 87 (13) : 7265 - 7281
  • [37] Investigation of Antibody Responses Induced in RV305 a Late Boost Vaccination of HIV-1 Uninfected Volunteers that Participated in RV144, a Thai Trial
    Karasavvas, N.
    Karnasuta, C.
    Ngauy, V.
    Vasan, S.
    Trichavaroj, R.
    de Souza, M. S.
    Savadsuk, H.
    Inthawong, D.
    Rittiroongrad, S.
    Madnote, S.
    Nitayaphan, S.
    Pitisuttithum, P.
    Rerks-Ngarm, S.
    O'Connell, R. J.
    Michael, N. L.
    Kim, J. H.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : A166 - A166
  • [38] Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
    RJ O'Connell
    VR Polonis
    S Ratto-Kim
    J Cox
    LL Jagodzinski
    J Malia
    NL Michael
    J Excler
    ML Robb
    JH Kim
    Retrovirology, 9
  • [39] ALVAC-HIV/AIDSVAX® B/E Late Boost Strategies (RV306) Increase the Proliferative Capacity of CD4+Effector Memory T Cells
    Schuetz, Alexandra
    Jongrakthaitae, Surat
    Eller, Michael
    Tragonlugsana, Nipattra
    Pitisutthithum, Punnee
    Nitayaphan, Sorachai
    Chariyalertsak, Suwat
    Kaewkungwal, Jaranit
    Excler, Jean-Louis
    Sinangil, Faruk
    Phogat, Sanjay
    Kim, Jerome
    Robb, Merlin
    Michael, Nelson
    Connell, Robert O.
    Vasan, Sandhya
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 170 - 170
  • [40] Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
    O'Connell, R. J.
    Polonis, V. R.
    Ratto-Kim, S.
    Cox, J.
    Jagodzinski, L. L.
    Malia, J.
    Michael, N. L.
    Excler, J.
    Robb, M. L.
    Kim, J. H.
    RETROVIROLOGY, 2012, 9
12345